Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia

医学 肝病学 肝移植 肝硬化 肝病 重症监护医学 内科学 移植
作者
Ashok Choudhury,Anand V. Kulkarni,Vinod Arora,A. S. Soin,A. Kadir Dökmeci,Abhijit Chowdhury,Abraham Koshy,Ajay Duseja,Ajay Kumar,Ajay Mishra,Ajay Kumar Patwa,Ajit Sood,Akash Roy,Akash Shukla,Albert C. Y. Chan,Aleksander Krag,Amar Mukund,Ameet Mandot,Amit Goel,Amna Subhan Butt
出处
期刊:Hepatology International [Springer Nature]
卷期号:19 (1): 1-69 被引量:2
标识
DOI:10.1007/s12072-024-10773-4
摘要

Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set in 2004 on ACLF was published in 2009, and the "APASL ACLF Research Consortium (AARC)" was formed in 2012. The AARC database has prospectively collected nearly 10,500 cases of ACLF from various countries in the Asia-Pacific region. This database has been instrumental in developing the AARC score and grade of ACLF, the concept of the 'Golden Therapeutic Window', the 'transplant window', and plasmapheresis as a treatment modality. Also, the data has been key to identifying pediatric ACLF. The European Association for the Study of Liver-Chronic Liver Failure (EASL CLIF) and the North American Association for the Study of the End Stage Liver Disease (NACSELD) from the West added the concepts of organ failure and infection as precipitants for the development of ACLF and CLIF-Sequential Organ Failure Assessment (SOFA) and NACSELD scores for prognostication. The Chinese Group on the Study of Severe Hepatitis B (COSSH) added COSSH-ACLF criteria to manage hepatitis b virus-ACLF with and without cirrhosis. The literature supports these definitions to be equally effective in their respective cohorts in identifying patients with high mortality. To overcome the differences and to develop a global consensus, APASL took the initiative and invited the global stakeholders, including opinion leaders from Asia, EASL and AASLD, and other researchers in the field of ACLF to identify the key issues and develop an evidence-based consensus document. The consensus document was presented in a hybrid format at the APASL annual meeting in Kyoto in March 2024. The 'Kyoto APASL Consensus' presented below carries the final recommendations along with the relevant background information and areas requiring future studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
众行绘研完成签到 ,获得积分10
刚刚
www完成签到 ,获得积分10
1秒前
shadow完成签到,获得积分10
2秒前
Iva完成签到 ,获得积分10
5秒前
坦率雪枫完成签到 ,获得积分10
7秒前
qwe完成签到,获得积分10
10秒前
G1997完成签到 ,获得积分10
13秒前
13秒前
赘婿应助科研通管家采纳,获得10
14秒前
14秒前
CY完成签到,获得积分10
14秒前
AA完成签到,获得积分10
15秒前
yan完成签到 ,获得积分10
16秒前
you完成签到 ,获得积分10
16秒前
道道sy完成签到,获得积分10
17秒前
潇洒冰蓝完成签到,获得积分10
17秒前
现代发布了新的文献求助10
19秒前
感动清炎完成签到,获得积分10
20秒前
nqterysc完成签到,获得积分10
29秒前
空蝉完成签到 ,获得积分10
31秒前
Suttier完成签到 ,获得积分10
31秒前
爱吃蓝莓果完成签到,获得积分10
32秒前
松柏完成签到 ,获得积分10
32秒前
Emily完成签到 ,获得积分10
33秒前
长情以蓝完成签到 ,获得积分10
35秒前
宇文宛菡完成签到 ,获得积分10
36秒前
芭乐王子完成签到 ,获得积分10
39秒前
yunxiao完成签到 ,获得积分10
46秒前
LMY完成签到 ,获得积分10
47秒前
wanghao完成签到 ,获得积分10
48秒前
晚风完成签到 ,获得积分10
52秒前
NIHAO完成签到 ,获得积分10
54秒前
weng完成签到,获得积分10
54秒前
TGU的小马同学完成签到 ,获得积分10
1分钟前
陈不沉完成签到 ,获得积分10
1分钟前
风中的小鸽子完成签到 ,获得积分10
1分钟前
幽默盼柳完成签到 ,获得积分10
1分钟前
阿拉完成签到,获得积分10
1分钟前
luobote完成签到 ,获得积分10
1分钟前
Yange完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Kinesiophobia : a new view of chronic pain behavior 5000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Digital Twins of Advanced Materials Processing 2000
Propeller Design 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 化学工程 生物化学 物理 计算机科学 内科学 复合材料 催化作用 物理化学 光电子学 电极 冶金 细胞生物学 基因
热门帖子
关注 科研通微信公众号,转发送积分 6013308
求助须知:如何正确求助?哪些是违规求助? 7581006
关于积分的说明 16140068
捐赠科研通 5160523
什么是DOI,文献DOI怎么找? 2763385
邀请新用户注册赠送积分活动 1743357
关于科研通互助平台的介绍 1634312